Loading...
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
The understanding of the B cell receptor (BCR) pathway and its contribution to chronic lymphocytic leukemia (CLL) pathogenesis have led to the development of targeted BCR inhibitors which have transformed the treatment paradigm of CLL. Ibrutinib is a first-in-class oral Bruton’s tyrosine kinase (BTK...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7936706/ https://ncbi.nlm.nih.gov/pubmed/33688166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S250823 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|